Cargando…

Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis

Recent years have observed the emergence of novel therapeutic opportunities for advanced hepatocellular carcinoma (HCC), such as combination therapies including immune checkpoint inhibitors. We performed a meta-analysis with the aim to compare median overall survival (OS), median progression-free su...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizzo, Alessandro, Ricci, Angela Dalia, Fanizzi, Annarita, Massafra, Raffaella, De Luca, Raffaele, Brandi, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858216/
https://www.ncbi.nlm.nih.gov/pubmed/36661706
http://dx.doi.org/10.3390/curroncol30010057
_version_ 1784874043750481920
author Rizzo, Alessandro
Ricci, Angela Dalia
Fanizzi, Annarita
Massafra, Raffaella
De Luca, Raffaele
Brandi, Giovanni
author_facet Rizzo, Alessandro
Ricci, Angela Dalia
Fanizzi, Annarita
Massafra, Raffaella
De Luca, Raffaele
Brandi, Giovanni
author_sort Rizzo, Alessandro
collection PubMed
description Recent years have observed the emergence of novel therapeutic opportunities for advanced hepatocellular carcinoma (HCC), such as combination therapies including immune checkpoint inhibitors. We performed a meta-analysis with the aim to compare median overall survival (OS), median progression-free survival (PFS), complete response (CR) rate, and partial response (PR) rate in advanced HCC patients receiving immune-based combinations versus sorafenib. A total of 2176 HCC patients were available for the meta-analysis (immune-based combinations = 1334; sorafenib = 842) and four trials were included. Immune-based combinations decreased the risk of death by 27% (HR, 0.73; 95% CI, 0.65–0.83; p < 0.001); similarly, a PFS benefit was observed (HR, 0.64; 95% CI, 0.5–0.84; p < 0.001). In addition, immune-based combinations showed better CR rate and PR rate, with ORs of 12.4 (95% CI, 3.02–50.85; p < 0.001) and 3.48 (95% CI, 2.52–4.8; p < 0.03), respectively. The current study further confirms that first-line immune-based combinations have a place in the management of HCC. The CR rate observed in HCC patients receiving immune-based combinations appears more than twelve times higher compared with sorafenib monotherapy, supporting the long-term benefit of these combinatorial strategies, with even the possibility to cure advanced disease.
format Online
Article
Text
id pubmed-9858216
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98582162023-01-21 Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis Rizzo, Alessandro Ricci, Angela Dalia Fanizzi, Annarita Massafra, Raffaella De Luca, Raffaele Brandi, Giovanni Curr Oncol Systematic Review Recent years have observed the emergence of novel therapeutic opportunities for advanced hepatocellular carcinoma (HCC), such as combination therapies including immune checkpoint inhibitors. We performed a meta-analysis with the aim to compare median overall survival (OS), median progression-free survival (PFS), complete response (CR) rate, and partial response (PR) rate in advanced HCC patients receiving immune-based combinations versus sorafenib. A total of 2176 HCC patients were available for the meta-analysis (immune-based combinations = 1334; sorafenib = 842) and four trials were included. Immune-based combinations decreased the risk of death by 27% (HR, 0.73; 95% CI, 0.65–0.83; p < 0.001); similarly, a PFS benefit was observed (HR, 0.64; 95% CI, 0.5–0.84; p < 0.001). In addition, immune-based combinations showed better CR rate and PR rate, with ORs of 12.4 (95% CI, 3.02–50.85; p < 0.001) and 3.48 (95% CI, 2.52–4.8; p < 0.03), respectively. The current study further confirms that first-line immune-based combinations have a place in the management of HCC. The CR rate observed in HCC patients receiving immune-based combinations appears more than twelve times higher compared with sorafenib monotherapy, supporting the long-term benefit of these combinatorial strategies, with even the possibility to cure advanced disease. MDPI 2023-01-05 /pmc/articles/PMC9858216/ /pubmed/36661706 http://dx.doi.org/10.3390/curroncol30010057 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Rizzo, Alessandro
Ricci, Angela Dalia
Fanizzi, Annarita
Massafra, Raffaella
De Luca, Raffaele
Brandi, Giovanni
Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis
title Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis
title_full Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis
title_fullStr Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis
title_full_unstemmed Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis
title_short Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis
title_sort immune-based combinations versus sorafenib as first-line treatment for advanced hepatocellular carcinoma: a meta-analysis
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858216/
https://www.ncbi.nlm.nih.gov/pubmed/36661706
http://dx.doi.org/10.3390/curroncol30010057
work_keys_str_mv AT rizzoalessandro immunebasedcombinationsversussorafenibasfirstlinetreatmentforadvancedhepatocellularcarcinomaametaanalysis
AT ricciangeladalia immunebasedcombinationsversussorafenibasfirstlinetreatmentforadvancedhepatocellularcarcinomaametaanalysis
AT fanizziannarita immunebasedcombinationsversussorafenibasfirstlinetreatmentforadvancedhepatocellularcarcinomaametaanalysis
AT massafraraffaella immunebasedcombinationsversussorafenibasfirstlinetreatmentforadvancedhepatocellularcarcinomaametaanalysis
AT delucaraffaele immunebasedcombinationsversussorafenibasfirstlinetreatmentforadvancedhepatocellularcarcinomaametaanalysis
AT brandigiovanni immunebasedcombinationsversussorafenibasfirstlinetreatmentforadvancedhepatocellularcarcinomaametaanalysis